Trials / Completed
CompletedNCT05848128
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Clinical Study to Assess the Efficacy and Safety of 5% Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 642 (actual)
- Sponsor
- Mimetogen Pharmaceuticals USA, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the efficacy and safety of 5% tavilermide ophthalmic solution to placebo for the treatment of the signs and symptoms of dry eye disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5% Tavilermide ophthalmic solution | Twice a day topicial dosing |
| OTHER | Vehicle ophthalmic solution | Twice a day topical dosing |
Timeline
- Start date
- 2023-06-28
- Primary completion
- 2024-05-11
- Completion
- 2024-05-11
- First posted
- 2023-05-08
- Last updated
- 2024-06-10
Locations
29 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05848128. Inclusion in this directory is not an endorsement.